This is a preview of subscription content, log in via an institution to check access.
References
Pass RF, Duliege A-M, Boppana SB, et al. Immunogenicity of a recombinant CMV gB vaccine. Pediatr Res 1995 Apr; 37 (Pt 2): 185
Duliege A-M, Frey S, Boppana S, et al. Recombinant CMV gB subunit vaccine with a novel adjuvant can significantly boost CMV antibody titers in CMV — seropositive adults. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep 17–20; San Francisco, 204
Marshall GS, Frey S, Pass R, et al. Safety and immunogenicity of CMV gB/MF59 vaccine in healthy seronegative adults. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28–Oct 1; Toronto, 228
Mitchell DK, Holmes SJ, Burke RL, et al. Immunogenicity of a recombinant human cytomegalovirus (CMV) gB vaccine in toddlers. Pediatr Res 1997 Apr; 41 (Pt 2): 127
Wang JB, Adler SP, Hempfling S, et al. Mucosal antibodies to human cytomegalovirus glycoprotein B occur following both natural infection and immunization with human cytomegalovirus vaccines. J Infect Dis 1996 Aug; 174: 387–92
Rights and permissions
About this article
Cite this article
Cytomegalovirus Glycoprotein Vaccine (Chiron). Drugs R&D 2, 308–309 (1999). https://doi.org/10.2165/00126839-199902050-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00126839-199902050-00005